Recent Company News

• 03:03 AM ET May 15, 2026
  

  BioArctic announces Eisai projects Leqembi revenue to total ¥143.5B for FY26 (SEK 329.40, +6.20)

• 02:46 AM ET May 15, 2026
  

  Eisai reports Q4 net income attributable (¥3.2B) vs FactSet ¥2.53B [4 est, (¥1.70)-7.63B] (¥4723.0000, 0)

• 02:16 PM ET May 13, 2026
  

  FDA approves sNDA for INQOVI combo for AML in adults 75+ years of age (¥11145.0000, 0)

• 01:15 PM ET May 11, 2026
  

  FDA provides safety update on Tazverik, confirms voluntary withdrawal from market (€164.50, 0.00)

• 05:09 AM ET May 10, 2026
  

  Shanghai Henlius Biotech obtains new indication approval from European Commission for slulimab injection (Hetronifly) (HK$73.55, 0.00)

• 02:36 AM ET May 08, 2026
  

  FDA extends Priority Review of Eisai's LEQEMBI IQLIK as starting dose for early Alzheimer's disease by three months (¥4677.0000, 0)

• 08:04 AM ET May 06, 2026
  

  Nuvation Bio announces FDA Acceptance of Supplemental NDA for IBTROZI with Updated Duration of Response in Advanced ROS1-Positive NSCLC ($4.83, 0.00)

• 02:34 PM ET May 01, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 3-May

• 06:04 AM ET Apr 29, 2026
  

  BioArctic notified by partner Eisai that global sales of Leqembi surpassed €500M in Eisai's FY25; triggers second sales-related milestone payment of €20M to BioArctic (SEK 312.00, +2.00)

• 02:26 PM ET Apr 24, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 26-Apr